Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin

F. Nicoletti, M. O. Borghi, P. L. Meroni, W. Barcellini, C. Fain, R. Di Marco, R. Menta, H. U. Schorlemmer, G. Bruno, G. Magro, S. Grasso

Research output: Contribution to journalArticlepeer-review


Ten out of 20 (50%) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.

Original languageEnglish
Pages (from-to)232-236
Number of pages5
JournalClinical and Experimental Immunology
Issue number2
Publication statusPublished - 1993


  • autoimmune diabetes
  • cyclophosphamide
  • deoxyspergualin
  • FK-506
  • interferon-gamma
  • NOD/ WEHI mouse

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin'. Together they form a unique fingerprint.

Cite this